Impact Factor
3.44
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.55
1,600 total citations
h5-index
35
h5 depth signal
Cited share
63.1%
410 of 650
Total citations
1,600
Citation footprint
Metric signal
2.32
External metric anchor
Self-citation
8.8%
141 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
766
United Kingdom
375
Canada
344
Italy
306
Germany
262
Citing Fields of Research
Neurodegenerative Disorders
1,453
Migraines & Headaches
480
Nervous System Disorders
412
Brain Neurological Disorders
375
Neurosciences
357
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,194
Articles tracked across the journal lifetime
Indexed publication set
650
410 cited publications
Last 12 months
470
39.2 publications/month
Open access share
39.8%
187 OA publications in the last year
Leading citing country
United States
766 citing publications
Leading citing field
Neurodegenerative Disorders
1,453 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v10n1, Jan. 2023-
v1n1, 2014-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Issuing & Sponsoring Bodies
issuing body
International Parkinson and Movement Disorder Society
Broad Categories
Neurology
Neurodegenerative Disorders
Migraines & Headaches
Neurosciences
Postural Control
MeSH Descriptors
Movement Disorders
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/mdc3.70854
Open DOI
Remote Video Assessment of Ataxia via SARA home : Correlation of Pose‐Derived Endpoints with Clinician Severity Ratings
Background: Remote assessment of ataxia is increasingly important for patient‐centered care and clinical research. SARA home , a validated video‐based adaptation of the Scale for the Assessment and Rating of Ataxia (SARA), enables self‐a...
02
DOI 10.1002/mdc3.70866
Open DOI
VPS13A Disease (Chorea‐Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations
Background: VPS13A disease is a very rare neurodegenerative disorder caused by mutations in the VPS13A gene. Its prevalence appears to be relatively high in Puerto Ricans, although limited genetic information has been available. Objectiv...
03
DOI 10.1002/mdc3.70857
Open DOI
Accuracy of Machine Learning in Differential Diagnosis of Multiple System Atrophy: A Systematic Review and Meta‐Analysis
Background: Multiple system atrophy (MSA) is frequently misdiagnosed as Parkinson's disease (PD) or progressive supranuclear palsy (PSP), posing significant diagnostic challenges. Objective: The aim of the study was to systematically eva...
04
DOI 10.1002/mdc3.70865
Open DOI
Prevalence and Associations of Abnormal Levels of Vitamin B6 in People with Parkinson's Disease
Background: In people with Parkinson's disease, abnormal levels of vitamin B6 may be associated with polyneuropathy and epileptic seizures, including medication‐refractory status epilepticus. Objectives: To estimate the prevalence and ex...
05
DOI 10.1002/mdc3.70861
Open DOI
Persistent Therapeutic Burden after Device‐Aided Therapy in Parkinson's Disease: Insights from Post‐ DAT MANAGE ‐ PD Assessment
Background: Device‐aided therapies (DAT) improve advanced Parkinson's disease (PD), but residual therapeutic burden may persist. Objectives: To explore MANAGE‐PD as a framework for characterizing residual disease burden after DAT. Method...
06
DOI 10.1002/mdc3.70851
Open DOI
Caregiver Burden and Its Determinants After Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease: A Cross‐Sectional Long‐Term Follow‐Up Study
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder, leading to increasing functional dependence even after deep brain stimulation (DBS). Although DBS improves motor outcomes, its long‐term impact on caregive...
07
DOI 10.1002/mdc3.70813
Open DOI
Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial
Background: Freezing of gait (FoG) belongs to most pressing unmet symptoms in the treatment of Parkinson's disease. Objectives: To explore whether combined subthalamic and nigral (STN + SNr) deep brain stimulation improves FoG compared w...
08
DOI 10.1002/mdc3.70862
Open DOI
Cervical Dystonia Treatment with Injections Supplemented by Transcranial Magnetic Stimulation: The D‐ TWIST Pilot Randomized Controlled Trial
Background: For some patients with cervical dystonia (CD), botulinum toxin (BoNT) injections last less than 12 weeks. Objectives: To determine if a novel, accelerated repetitive transcranial magnetic stimulation (rTMS) protocol is a safe...
09
DOI 10.1002/mdc3.70863
Open DOI
Genotype–Phenotype Correlations in THAP1 ‐Associated Dystonia: A Multicentric Observational Study
Background: DYT‐ THAP1 is a recognized cause of early‐onset isolated dystonia. However, available data are largely derived from European cohorts, limiting understanding of genetic diversity, phenotype variability, and treatment response ...
10
DOI 10.1002/mdc3.70818
Open DOI
Pregabalin in Dopamine Dysregulation Syndrome
Bibliographical & Catalog Notes
Numbering from content page.
Official journal of the International Parkinson and Movement Disorder Society.